P
Ping Li
Researcher at Nanchang University
Publications - 106
Citations - 5685
Ping Li is an academic researcher from Nanchang University. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 33, co-authored 104 publications receiving 4807 citations. Previous affiliations of Ping Li include International Council for the Exploration of the Sea & Chengdu Medical College.
Papers
More filters
Journal ArticleDOI
Chronic Dialysis and Death Among Survivors of Acute Kidney Injury Requiring Dialysis
TL;DR: Acute kidney injury necessitating in-hospital dialysis was associated with an increased risk of chronic dialysis but not all-cause mortality, and the primary end point was the need for chronicdialysis.
Journal ArticleDOI
Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding
Muhammad Mamdani,Kathy Sykora,Ping Li,Sharon-Lise T. Normand,David L. Streiner,Peter C. Austin,Paula A. Rochon,Geoffrey M. Anderson +7 more
TL;DR: The definition and assessment of confounders is focused on, where age is known to be related to risk of hip fracture and therefore has the potential to be a confounder in the study of the association between antipsychotic use and hip fracture.
Journal ArticleDOI
Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis
TL;DR: The protective association between statins and sepsis persisted in high-risk subgroups, including patients with diabetes mellitus, chronic renal failure, or a history of infections, who survived for at least 3 months after discharge.
Journal ArticleDOI
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.
Sudeep S. Gill,Geoffrey M. Anderson,Hadas D. Fischer,Chaim M. Bell,Ping Li,Sharon-Lise T. Normand,Paula A. Rochon +6 more
TL;DR: Use of cholinesterase inhibitors is associated with increased rates of syncope, bradycardia, pacemaker insertion, and hip fracture in older adults with dementia, and the risk of these previously underrecognized serious adverse events must be weighed carefully against the drugs' generally modest benefits.